Researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, have shown that the amount of a protein called CD74 can indicate which people with bowel cancer ...
Figure 6: Tumor infiltrating immune cell profiling according to high (cyan) and low (salmon) CD74:MIF levels (A) and CD74:DDT levels (B) using TIMER2.0 deconvolution analysis. “[...] we present the ...
Oncotarget | Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001
“Taken together, these findings provide a strong rationale for potently and selectively targeting of CD74 in patients with B-NHL [B-cell non-Hodgkin lymphoma].” BUFFALO, NY- January 17, 2023 – A new ...
Preclinical activity of the Hsp90 inhibitor, ganetespib, in ALK- and ROS1-driven cancers. BI 836845, a fully human IGF ligand neutralizing antibody, to improve the efficacy of rapamycin by blocking ...
Researchers have shown that the amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy. Researchers at the Francis Crick Institute and Barts ...
A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, "Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001." In this new study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results